GlassScriptPhysician profile
Jeffrey B Eskind
NPI 1972543205
$7,863.30
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,114 · 2020: $1,020 · 2021: $2,255 · 2022: $2,123 · 2023: $1,329 · 2024: $21.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,351.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,350.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $1,728.84 | 2019-2023 | Entyvio |
| Abbvie INC. | $1,687.87 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,623.10 | 2019-2024 | Trulance, Xifaxan |
| Merck Sharp & Dohme LLC | $512.21 | 2020-2023 | Dificid |
| Janssen Biotech, INC. | $506.25 | 2019-2023 | Stelara, Remicade, Simponi |
| Qol Medical, LLC | $322.33 | 2019-2022 | |
| Evoke Pharma, INC. | $225.92 | 2020-2023 | Gimoti |
| Nestle Healthcare Nutrition INC. | $216.34 | 2020-2023 | |
| Genzyme Corporation | $193.82 | 2022-2023 | |
| Daiichi Sankyo INC. | $150.33 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $145.04 | 2019-2022 | |
| Concordia Pharmaceuticals INC. | $116.92 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $99.30 | 2023 | Dupixent |
| Pfizer INC. | $74.71 | 2019-2023 | |
| Allergan, INC. | $61.21 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $49.30 | 2019-2023 | Avsola, Amjevita |
| Romark Laboratories, Lc | $42.84 | 2019 | |
| Redhill Biopharma INC. | $37.71 | 2020-2022 | |
| Intercept Pharmaceuticals, INC. | $20.71 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.03 | 2023 | Cyltezo |
| Ferring Pharmaceuticals INC. | $16.41 | 2020 | |
| Edwards Lifesciences Corporation | $15.11 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Eskind listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.